The mistake was the inclusion of ventilator dependency. You can see why it happened, at the time of this trial ventilation was deemed the best care available and a requirement for moderate/severe Covid-ARDS, it was pretty much the benchmark for how the disease progresses and the world rushed to make ventilators thinking they would run out. Then analysis of results under ventilation showed that it may even be damaging the patients so it quickly became a last resort and well after the time it was being applied earlier in our response to serious cases of Covid-19.
The way to avoid this to to stick to objective pathology criteria rather than the commencement of a particular treatment or the time of admission to hospital etc. CT scans of lungs and blood pathology was enough to provide a clear and objective determination of disease severity and they should have left it at that. Hindsight is great that way. I expect that the delays in ventilation with evolving SOC were a significant reason why enrolment was so slow. It would not surprise me if the opposite of what people are surmising (that SOC reduced death rates) is true, that placebo death rates actually climbed significantly across the trial period - but so did the treated arm - and the gap narrowed dramatically.
I hope the unmasked stats allow for a date based evaluation of the data so that this can be explored - if ventilation delay is causing the placebo arm to also show increased mortality then it would be clear that the timing of first medication is the key to whether Rem-L (or perhaps any treatment) can be effective.
- Forums
- ASX - By Stock
- Ann: Mesoblast Update on COVID-19 ARDS Trial
The mistake was the inclusion of ventilator dependency. You can...
- There are more pages in this discussion • 390 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.18 |
Change
0.020(1.73%) |
Mkt cap ! $1.341B |
Open | High | Low | Value | Volume |
$1.20 | $1.21 | $1.17 | $16.67M | 14.04M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 54704 | $1.18 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.18 | 10000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 54704 | 1.175 |
16 | 356446 | 1.170 |
5 | 104564 | 1.165 |
60 | 284754 | 1.160 |
10 | 99946 | 1.155 |
Price($) | Vol. | No. |
---|---|---|
1.180 | 10000 | 1 |
1.190 | 17537 | 2 |
1.195 | 39915 | 3 |
1.200 | 50095 | 3 |
1.205 | 164344 | 2 |
Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
Last
$1.19 |
  |
Change
0.020 ( 3.40 %) |
|||
Open | High | Low | Volume | ||
$1.21 | $1.21 | $1.17 | 2927691 | ||
Last updated 15.59pm 07/05/2024 ? |
Featured News
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
Previous Video
Next Video
SPONSORED BY The Market Online